biote (BTMD) Competitors $5.09 -0.44 (-7.96%) As of 01/31/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends BTMD vs. ARVN, OCUL, RCUS, SNDX, CALT, AUPH, ADPT, COLL, NTLA, and SYREShould you be buying biote stock or one of its competitors? The main competitors of biote include Arvinas (ARVN), Ocular Therapeutix (OCUL), Arcus Biosciences (RCUS), Syndax Pharmaceuticals (SNDX), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Adaptive Biotechnologies (ADPT), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry. biote vs. Arvinas Ocular Therapeutix Arcus Biosciences Syndax Pharmaceuticals Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals Adaptive Biotechnologies Collegium Pharmaceutical Intellia Therapeutics Spyre Therapeutics biote (NASDAQ:BTMD) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking. Which has more risk & volatility, BTMD or ARVN? biote has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Does the media prefer BTMD or ARVN? In the previous week, biote had 3 more articles in the media than Arvinas. MarketBeat recorded 7 mentions for biote and 4 mentions for Arvinas. Arvinas' average media sentiment score of 0.47 beat biote's score of 0.34 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, BTMD or ARVN? biote has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$193.06M1.43$3.32M$0.2619.58Arvinas$78.50M15.41-$367.30M-$4.67-3.77 Is BTMD or ARVN more profitable? biote has a net margin of 5.20% compared to Arvinas' net margin of 0.00%. biote's return on equity of -32.41% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets biote5.20% -32.41% 22.26% Arvinas N/A -50.26%-24.87% Do analysts rate BTMD or ARVN? biote presently has a consensus price target of $10.00, suggesting a potential upside of 96.46%. Arvinas has a consensus price target of $62.91, suggesting a potential upside of 257.24%. Given Arvinas' higher possible upside, analysts clearly believe Arvinas is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Arvinas 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Do insiders and institutionals hold more shares of BTMD or ARVN? 21.7% of biote shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 13.9% of biote shares are held by company insiders. Comparatively, 5.2% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in BTMD or ARVN? Arvinas received 171 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 67.03% of users gave Arvinas an outperform vote. CompanyUnderperformOutperformbioteOutperform Votes14100.00% Underperform VotesNo VotesArvinasOutperform Votes18567.03% Underperform Votes9132.97% Summarybiote beats Arvinas on 11 of the 18 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$300.48M$1.18B$5.56B$9.11BDividend YieldN/AN/A5.31%3.98%P/E Ratio19.5833.0089.9918.25Price / Sales1.435.871,221.9274.93Price / Cash11.419.6345.9637.70Price / Book-8.781.975.124.71Net Income$3.32M-$53.10M$111.09M$224.24M7 Day Performance-7.62%-3.02%2.38%1.08%1 Month Performance-17.64%-5.57%3.20%1.51%1 Year Performance27.25%-13.93%24.70%20.44% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.9487 of 5 stars$5.09-8.0%$10.00+96.5%+34.3%$308.64M$185.36M19.58194Short Interest ↑News CoverageGap DownHigh Trading VolumeARVNArvinas2.2702 of 5 stars$18.21+0.4%$63.50+248.7%-57.6%$1.25B$78.50M-3.90420OCULOcular Therapeutix3.4268 of 5 stars$7.89-1.0%$16.71+111.8%+58.4%$1.24B$58.44M-5.98230RCUSArcus Biosciences1.6742 of 5 stars$13.42+2.0%$34.00+153.3%-14.4%$1.23B$117M-4.26500SNDXSyndax Pharmaceuticals3.5965 of 5 stars$14.250.0%$36.20+154.1%-30.8%$1.22BN/A-3.92110Short Interest ↑CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.0422 of 5 stars$8.26+3.3%$10.00+21.1%+5.4%$1.18B$175.51M-55.06300Short Interest ↑News CoverageADPTAdaptive Biotechnologies3.507 of 5 stars$7.70-3.6%$6.75-12.3%+111.2%$1.14B$170.28M-5.75790Analyst ForecastPositive NewsCOLLCollegium Pharmaceutical4.3591 of 5 stars$33.91+4.1%$43.80+29.2%-2.5%$1.09B$566.77M14.62210Positive NewsNTLAIntellia Therapeutics4.6964 of 5 stars$10.55-4.0%$48.71+361.7%-56.7%$1.07B$36.28M-1.94600Analyst RevisionGap DownSYRESpyre Therapeutics2.0922 of 5 stars$20.82-3.6%$54.83+163.4%-11.3%$1.07B$890,000.00-2.79100 Related Companies and Tools Related Companies Arvinas Alternatives Ocular Therapeutix Alternatives Arcus Biosciences Alternatives Syndax Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives Aurinia Pharmaceuticals Alternatives Adaptive Biotechnologies Alternatives Collegium Pharmaceutical Alternatives Intellia Therapeutics Alternatives Spyre Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BTMD) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
